RxDoctor Payments Data

Richard Bisbing, MD

Family Medicine · Shermans Dale, PANPI 1134139082

Payments from drug & device makers

$5,152in general payments, 2019–2025

Across 335 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Lilly USA, LLC$336
  • Pfizer$310
  • E.r. Squibb & Sons, L.L.C.$59
  • Sanofi-aventis U.S. LLC$57
  • Merck$39
  • plus $194 from 10 others

What the payments were for

  • Food & beverage$5,152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,152 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$162,326
Medicare patients
318
Services billed
2,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin290$169,105
EliquisApixaban321$155,676
OzempicSemaglutide95$142,583
JanuviaSitagliptin Phosphate73$62,826
MounjaroTirzepatide23$60,430
TrulicityDulaglutide56$60,407
XareltoRivaroxaban124$55,184
Tresiba Flextouch U-200Insulin Degludec43$45,452
Xultophy 100-3.6Insulin Degludec/Liraglutide13$38,276
RybelsusSemaglutide15$38,063
TradjentaLinagliptin206$33,154
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$31,357
Lantus SolostarInsulin Glargine,hum.Rec.Anlog136$16,853
Atorvastatin Calcium1,343$15,243
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp34$13,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus$4,158$218,921123 claims
Boehringer IngelheimJardiance, Tradjenta$22$202,258496 claims
PfizerEliquis$310$155,676321 claims
Lilly USA, LLCMounjaro, Trulicity$336$120,83679 claims
MerckJanuvia$39$62,82673 claims
Johnson & JohnsonXarelto$38$55,184124 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Shingrix, Arexvy$20$54,474115 claims
AstraZenecaLokelma, Symbicort$27$11,71932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Shermans Dale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →